LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cardiac Troponin Assays Compared in Large Cohort

By LabMedica International staff writers
Posted on 19 Nov 2018
Image: The automatic immunoassay analyzer / chemiluminescence ARCHITECT i1000SR (Photo courtesy of Abbott Diagnostics).
Image: The automatic immunoassay analyzer / chemiluminescence ARCHITECT i1000SR (Photo courtesy of Abbott Diagnostics).
High-sensitivity (hs) assays for the measurement of cardiac troponin T (cTnT) and cardiac troponin I (cTnI) are now used widely for the diagnosis of myocardial infarction. The universal definition of myocardial infarction recommends the 99th centile derived from a normal reference population be used to define myocardial necrosis.

However, it is also increasingly apparent that troponin concentrations well below this threshold provide diagnostic and prognostic information for patients with both acute and stable cardiovascular diseases and may have a role in screening the general population. Few studies have measured both cTnI and cTnT in a single large general population cohort.

A group of cardiology scientists mainly from the University of Glasgow (Glasgow, UK) measured troponins in serum from 19,501 individuals in the Generation Scotland Scottish Family Health Study. Associations with cardiovascular risk factors were compared using age- and sex-adjusted regression. Observed age- and sex-stratified 99th centiles were compared with 99th centiles for cTnT (men, 15.5 ng/L; women, 9.0 ng/L) and cTnI (men, 34.2 ng/L; women, 15.6 ng/L) used in clinical practice.

The team measured hs-cTnT and hs-cTnI on Cobas e411 and i1000SR analyzers, respectively. Both assays were calibrated and quality controlled using the manufacturer's reagents. Coefficients of variations (CVs) for cTnI were 6.2% for the low control, 6.0% for intermediate control, and 4.6% for high control. CVs for cTnT were 5.0% for the low control and 3.4% for the high control.

The team reported that cTnT and cTnI concentrations were detectable in 53.3% and 74.8% of participants, respectively, and were modestly correlated in unadjusted analyses (R2 = 21.3%) and only weakly correlated after adjusting for age and sex (R2 = 9.5%). Cardiovascular risk factors were associated with both troponins, but in age- and sex-adjusted analyses, cTnI was more strongly associated with age, male sex, body mass index, and systolic blood pressure. cTnT was more strongly associated with diabetes. The observed 99th centiles were broadly consistent with recommended 99th centiles in younger men and women. After the age of 60 years, observed 99th centiles increased substantially for cTnT, and beyond 70 years of age, the 99th centiles approximately doubled for both troponins.

The authors concluded in a large cohort study from a general population, cTnT and cTnI concentrations are differentially associated with cardiovascular risk factors and are weakly correlated with each other. Existing sex-specific 99th centiles are broadly appropriate for both men and women up to the age of 60 years. Beyond the age of 70 years, the 99th centile is approximately three-fold higher for cTnT in both men and women and two-fold higher for cTnI in women. The study was published in the October 2018 issue of the journal Clinical Chemistry.

Related Links:
University of Glasgow

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more